Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Positive predictive values for separate factors and combination of presence of ANAs and methotrexate treatment for development of infusion reactions in RA patients

From: Predictors of infusion reactions during infliximab treatment in patients with arthritis

Factors Patients (n) OR 95% CI P
ANA positivity 56 2.1 1.04–4.29 0.040a
Infliximab without methotrexate 84 3.1 1.53–6.29 0.002a
Infliximab as monotherapy 46 3.6 1.73–7.14 0.001a
ANA positive + MTX no 26 4.6 1.61–13.15 0.004b
ANA positive + MTX yes 30 2.2 0.74–6.36 0.161b
ANA negative + MTX yes 93 1.0 - -
ANA negative + MTX no 52 3.3 1.35–8.06 0.009b
  1. aAdjusted for age, sex and prednisolone at start. bAdjusted for age, sex and disease duration. ANA, antinuclear antibody; CI, confidence interval; MTX, methotrexate; OR, odds ratio; RA, rheumatoid arthritis.